Erratum: A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronies disease (BJU International (2010) 106:2 (240-8) doi: 10.1111/j.1464-410X.2009.09041.x);A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease

BJU International

Volumn 106, Issue 2, 2010, Pages 240-248

  Safarinejad, Mohammad Reza ^a   Asgari, Majid Ali ^a   Hosseini, Seyyed Yousof ^a   Dadkhah, Farid ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

erectile dysfunction; pentoxifylline; Peyronie's disease; treatment

Indexed keywords

4 AMINOBENZOATE POTASSIUM; ALPHA TOCOPHEROL; APO PENTOXIFYLLINE; COLCHICINE; PENTOXIFYLLINE; PLACEBO; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ECHOGRAPHY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN ASSESSMENT; PATIENT SATISFACTION; PENIS ERECTION; PEYRONIE DISEASE; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEXUAL INTERCOURSE; SUSTAINED RELEASE FORMULATION; TREMOR; VERTIGO; VISUAL ANALOG SCALE; VOMITING; X RAY;

EID: 77953831177     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.13063     Document Type: Erratum

References (31)

1. Gholami SS, Gonzalez-Cadavid NF, Lin CS et al. Peyronie's disease: a review. J Urol 2003 169 : 1234 1241
2. Cormio L, Zucchi A, Lorusso F et al. Surgical treatment of Peyronie's disease by plaque incision and grafting with buccal mucosa. Eur Urol 2009 55 : 1469 1475
3. Jarow JP, Lowe FC. Penile trauma: an etiologic factor in Peyronie's disease and erectile dysfunction. J Urol 1997 158 : 1388 1390
4. Haag SM, Hauck EW, Eickelberg O et al. Investigation of the antifibrotic effect of IFN-gamma on fibroblasts in a cell culture model of Peyronie's disease. Eur Urol 2008 53 : 425 430
5. Williams JL, Thomas GG. The natural history of Peyronie's disease. J Urol 1970 103 : 75 6
6. Kadioglu A, Tefekli A, Erol H et al. A retrospective review of 307 men with Peyronie's disease. J Urol 2002 168 : 1075 1079
7. Levine LA. Seeking answers on the quest for effective nonsurgical treatment of Peyronie's disease. Eur Urol 2007 51 : 601 603
8. Biagiotti G, Cavallini G. Acetyl-l-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int 2001 88 : 63 7
9. Hauck EW, Diemer T, Schmelz HU et al. A critical analysis of nonsurgical treatment of Peyronie's disease. Eur Urol 2006 49 : 987 997
10. Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int J Impot Res 2004 16 : 238 243
11. Safarinejad MR, Hosseini SY, Kolahi AA. Comparison of vitamin E and propionyl-l-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol 2007 178 : 1398 1403
12. Safarinejad MR. Efficacy and safety of omega-3 for treatment of early-stage Peyronie's disease: a prospective, randomized, double-blind placebo-controlled study. J Sex Med 2009 6 : 1743 1754
13. Raetsch C, Jia JD, Boigk G et al. Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut 2002 50 : 241 247
14. Schandené L, Vandenbussche P, Crusiaux A et al. Differential effects of pentoxifylline on the production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) by monocytes and T cells. Immunology 1992 76 : 30 4
15. Menon RT, Feferman T, Aricha R et al. Suppression of experimental autoimmune myasthenia gravis by combination therapy: pentoxifylline as a steroid-sparing agent. J Neuroimmunol 2008 201-202 : 128 135
16. Lischer GH, Nehra A. New advances in Peyronie's disease. Curr Opin Urol 2001 11 : 631 636
17. Prasad K, Lee P. Suppression of hypercholesterolemic atherosclerosis by pentoxifylline and its mechanism. Atherosclerosis 2007 192 : 313 322
18. Cappelleri JC, Rosen RC, Smith MD et al. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999 54 : 346 351
19. Rosen RC, Riley A, Wagner G et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997 49 : 822 830
20. Montorsi F, Guazzoni G, Bergamaschi F et al. Vascular abnormalities in Peyronie's disease. The role of color Doppler sonography. J Urol 1994 151 : 373 375
21. Wilkins CJ, Sriprasad S, Sidhu PS. Colour Doppler ultrasound of the penis. Clin Radiol 2003 58 : 514 523
22. Kelami A. Classification of congenital and acquired penile deviation. Urol Int 1983 38 : 829 833
23. Kapetanos D, Kokozidis G, Christodoulou D et al. A randomized controlled trial of pentoxifylline for the prevention of post-ERCP pancreatitis. Gastrointest Endosc 2007 66 : 513 518
24. Windmeier C, Gressner AM. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol 1997 29 : 181 196 (Pubitemid 27312367)
25. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990 144 : 1376 1379
26. Venkitaraman R, Price A, Coffey J et al. Pentoxifylline to treat radiation proctitis: a small and inconclusive randomised trial. Clin Oncol (R Coll Radiol) 2008 20 : 288 292
27. Louvet A, Diaz E, Dharancy S et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008 48 : 465 470
28. Maiti R, Agrawal NK, Dash D et al. Effect of Pentoxifylline on inflammatory burden, oxidative stress and platelet aggregability in hypertensive type 2 diabetes mellitus patients. Vascul Pharmacol 2007 47 : 118 124 (Pubitemid 47095453)
29. Haag SM, Hauck EW, Szardening-Kirchner C et al. Alterations in the transforming growth factor (TGF) -beta pathway as a potential factor in the pathogenesis of Peyronie's disease. Eur Urol 2007 51 : 255 261
30. Fernandes JL, de Oliveira RT, Mamoni RL et al. Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease - a randomized placebo-controlled study. Atherosclerosis 2008 196 : 434 442
31. Valente EG, Vernet D, Ferrini MG et al. l-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003 9 : 229 244